

### The company

Corporis Medical is a young medical device company which started its operations in 2015, focusing on developing innovative solutions for improving access, closure, and diagnostic measurements for minimally invasive interventional procedures. The company has several products in development in collaboration with a KOL, designers, suppliers, and distributors. Our primary product, Mediclose™, is designed to automatically close trocar induced wounds at the end of laparoscopic surgery.

### Mediclose™

Mediclose™ is our **sterile, disposable, and automated suturing device**. Its **unique design** that fits any commercial trocar allows for extremely fast closure (wounds can be closed within a minute). Furthermore, its one-hand activation makes this device easy to use. As such, Mediclose™ reduces time necessary to close trocar induced wounds and significantly lowers the risk of a post-surgery herniation. Lastly, most existing suture systems close the trocar induced incisions from outside inward, while the Mediclose™ system was designed to close incision from inside outward, with the position of the needles pointing away from any vital organs. Therefore, Mediclose™ presents a **safer and faster** way of trocar wound closure, which not only saves valuable time but also limited health care resources.



**Mediclose™ application steps:** 1) insert device in trocar and connect to adaptor, 2) activate spreading mechanism and activate the Mediclose™ needles, 3) lift trocar + Mediclose™ from the wound, then cut and tie the suture.

### The market opportunities

Laparoscopic surgery is quickly gaining ground in all fields of surgery due to its enhanced recovery. It is estimated that there are upwards to 20 million laparoscopic procedures performed worldwide every year. For the EU and the US combined, this sums up to ~10 million laparoscopic surgeries performed annually. Currently, Mediclose™ is starting its human clinical trials. CE-mark approval and sales are expected in 2024.

### Distribution and commercial partnerships

With a total market of 10 million laparoscopic procedures yearly, Corporis Medical could save and improve thousands of lives with their new laparoscopic interventions. **Corporis Medical is continuously looking to expand its network of distributors specialized in surgical tools and selling directly to hospitals and/or partners to incorporate Mediclose™ as part of their laparoscopic surgical tools portfolios or trocar kits.**

For more information about MEDICLOSE™, please contact our project manager Simone Schols.

# Mediclose™ Device

Year to date Milestones 2023	
<b>Funding</b>	Pre-seed €600K (2015) Series A (2018/2020) at €5M
<b>Patents</b>	2 patent families
<b>Trade Marks</b>	MEDICLOSE™
<b>QA - QMS</b>	ISO13485 certified
<b>Regulatory</b>	MEDICLOSE™ class 3
<b>Focus 2023</b>	Clinical assessment
<b>Stage of Development</b>	First-in-human ongoing
<b>MEDICLOSE™</b>	Large scale manufacturing and Supply Chain in place
<b>Outlook</b>	Next generation: semi re-usable device

Contact Details	
<b>Corporis Medical</b> Oxfordlaan 55 6229 EV Maastricht The Netherlands	Simone Schols, Project Mgr. T: +31 6 81794791 E: <a href="mailto:simone.schols@corporis-medical.com">simone.schols@corporis-medical.com</a>